Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy

Journal of Nuclear Medicine

Volumn 48, Issue 1, 2007, Pages 134-142

  Konijnenberg, Mark ^a   Melis, Marleen ^b   Valkema, Roelf ^b   Krenning, Eric ^b   De Jong, Marion ^b  

^a Mallinckrodt Medical BV   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

111In DTPA octreotide; 177Lu DOTA octreotate; 90Y DOTA octreotide; Dose volume histogram; Kidney dosimetry; Radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[3 TYROSINE] LUTETIUM 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] YTTRIUM 90; LUTETIUM 177; OCTREOTIDE[3 TYROSINE]; PENTETATE INDIUM IN 111; UNCLASSIFIED DRUG; YTTRIUM 90; DIAGNOSTIC AGENT; HETEROCYCLIC COMPOUND; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; RECEPTOR; YTTRIUM(III) 1,4,7,10 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETIC ACID; YTTRIUM(III)-1,4,7,10-TETRAAZACYCLOTETRADECANE-N,N',N'',N'''-TETRAACETIC ACID;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; AUTORADIOGRAPHY; BETA RADIATION; BRAIN CORTEX; CLINICAL ARTICLE; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; EXTERNAL BEAM RADIOTHERAPY; GAMMA RADIATION; HISTOGRAM; HUMAN; KIDNEY; KIDNEY TUMOR; MALE; MEDULLA OBLONGATA; MONTE CARLO METHOD; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; CHEMISTRY; IMAGE PROCESSING; METABOLISM; METHODOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOMETRY; SCINTISCANNING; STATISTICAL MODEL; THREE DIMENSIONAL IMAGING;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HETEROCYCLIC COMPOUNDS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; KIDNEY; MODELS, STATISTICAL; MONTE CARLO METHOD; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, PEPTIDE;

EID: 33847306528     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. 3-octreotate. J Nucl Med. 2005;46(suppl):83S-91S.
2. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys. 1995;31:1249-1256.
3. 86Y. Eur J Nucl Med Mol Imaging. 2003;30:354-361.
4. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847-851.
5. 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552-1554.
6. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(suppl):99S-106S.
7. 3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm. 2003;18:619-625.
8. Bouchet LG, Bolch WE, Blanco HP, et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113-1147.
9. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm. 2004;19:363-370.
10. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
11. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110-122.
12. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386-1392.
13. 111In-DTPA] octreotide. J Nucl Med. 2004;45:1168-1171.
14. Adelstein SJ, Green AJ, Howell RW, et al. ICRU report 67: absorbed-dose specification in nuclear medicine. J ICRU. 2002;2:64-65.
15. Las Alamos National Laboratory Report: LA-UR-03-1987; MCNP - A general Monte Carlo N-particle transport code [report on CD-ROM]. Version 5. Booth TE, Brown FB, Bull JS, et al., eds. Las Alamos, NM: Las Alamos National Laboratory; 2003.
16. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
17. Kutcher GJ, Burman C. Calculation of complication probability factors for nonuniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 1989;16:1623-1630.
18. Kutcher GJ, Burman C, Brewster L, Goitein M, Mohan R. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys. 1991;21:137-146.
19. Flynn AA, Pedley RB, Green AJ, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res. 2003;159:182-189.
20. Olsen DR, Kambestad BK, Kristoffersen DT. Calculation of radiation induced complication probabilities for brain, liver and kidney, and the use of a reliability model to estimate critical volume fractions. Br J Radiol. 1994;67:1218-1225.
21. Skov K, Nyengaard JR, Patwardan A, Mulrany MJ. Large juxtamedullary glomeruli and afferent arterioles in healthy primates. Kidney Int. 1999;55:1462-1469.
22. Newbold KM, Sandison A, Howie AJ. Comparison of size of juxtamedullary and outer cortical glomeruli in normal adult kidney. Virchows Arch A Pathol Anat Histopathol. 1992;420:127-129.
23. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123-135.
24. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.